The pathology of APP transgenic mice: A model of Alzheimer's disease or simply overexpression of APP?

Histology and Histopathology

Volumn 24, Issue 1, 2009, Pages 83-100

  Howlett, David R ^a   Richardson, J C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid plaques; Neurodegenerative pathology

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CLIOQUINOL; CURCUMIN; IBUPROFEN; LITHIUM; MUTANT PROTEIN; OLIGOMER; PENTAPEPTIDE; PIOGLITAZONE; TAU PROTEIN;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ASTROCYTE; BRAIN ATROPHY; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CELL LOSS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; INFLAMMATORY CELL; MEMORY DISORDER; MICROGLIA; MUTATIONAL ANALYSIS; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PATHOLOGICAL ANATOMY; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SENILE PLAQUE; STRAIN DIFFERENCE; TRANSGENE; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; BRAIN; GENETICS; METABOLISM; MOUSE; PATHOLOGY;

MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC;

EID: 60549116540     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Adlard P.A., Perreau V.M., Pop V. and Cotman C.W. (2005). Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 4217-4221.
2. Arendash G.W., Gordon M.N., Diamond D.M., Austin L.A., Hatcher J.M., Jantzen P., DiCarlo G., Wilcock D. and Morgan D. (2001). Behavioral assessment of Alzheimer's transgenic mice following long-term A beta vaccination: Task specificity and correlations between A beta deposition and spatial memory. DNA Cell Biol. 20, 737-744.
3. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D. and Yednock T. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919.
4. Barten D.M., Guss V.L., Corsa J.A., Loo A., Hansel S.B., Zheng M., Munoz B., Srinivasan K., Wang B., Robertson B.J., Polson C.T., Wang J., Roberts S.B., Hendrick J.P., Anderson J.J., Loy J.K., Denton R., Verdoorn T.A., Smith D.W. and Felsenstein K.M. (2005). Dynamics of beta-amyloid reductions in brain, cerebrospinal fluid, and plasma of beta-amyloid precursor protein transgenic mice treated with a gamma-secretase inhibitor. J. Pharm. Exp. Therap. 312, 635-643.
5. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B. and Berger M. (1991). Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285, 111-114.
6. Blasko I., Veerhuis R., Stampfer-Kountchev M., Saurwein-Teissl M., Eikelenboom P. and Grubeck-Loebenstein B. (2000). Costimulatory effects of interferon-gamma and interleukin-1 beta or tumor necrosis factor alpha on the synthesis of a beta 1-40 and a beta 1-42 by human astrocytes. Neurobiol. Dis. 7, 682-689.
7. Bondolfi L., Calhoun M., Ermini F., Kuhn H.G., Wiederhold K.H., Walker L., Staufenbiel M. and Jucker M. (2002). Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J. Neurosci. 22, 515-522.
8. Borchelt D.R., Ratovitski T., Vanlare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L. and Sisodia S.S. (1997). Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin-1 and amyloid precursor proteins. Neuron 19, 939-945.
9. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G. and Sisodia S.S. (1996). Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013.
10. Boyett K.W., DiCarlo G., Jantzen P.T., Jackson J., O'Leary C., Wilcock D., Morgan D. and Gordon M.N. (2003). Increased fibrillar beta-amyloid in response to human C1q injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem. Res. 28, 83-93.
11. Braak H. and Braak E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259.
12. Breitner J.C., Gau B.A., Welsh K.A., Plassman B.L., McDonald W.M., Helms M.J. and Anthony J.C. (1994). Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44, 227-232.
13. Burbach G.J., Vlachos A., Ghebremedhin E., Del Turco D., Coomaraswamy J., Staufenbiel M., Jucker M. and Deller T. (2007). Vessel ultrastructure in APP23 transgenic mice after passive anti-Aβ immunotherapy and subsequent intracerebral hemorrhage. Neurobiol. Aging 28, 202-212.
14. Buttini M., Masliah E., Barbour R., Grajeda H., Motter R., Johnson-Wood K., Khan K., Seubert P., Freedman S., Schenk D. and Games D. (2005). Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J. Neurosci. 25, 9096-9101.
15. Caccamo A., Oddo S., Tran L.X. and Laferla F.M. (2007). Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol. 170, 1669-1675.
16. Calhoun M.E., Burgermeister P., Phinney A.L., Stalder M., Tolnay M., Wiederhold K.H., Abramowski D., Sturchler-Pierrat C., Sommer B., Staufenbiel M. and Jucker M. (1999). Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. USA 96, 14088-14093.
17. Capsoni S. and Cattaneo A. (2006). On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease. Cell. Mol. Neurobiol. 26, 619-633.
18. Capsoni S., Ugolini G., Comparini A., Ruberti F., Berardi N. and Cattaneo A. (2000). Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc. Natl. Acad. Sci. USA 97, 6826-6831.
19. Capsoni S., Giannotta S. and Cattaneo A. (2002). Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies. Cell. Mol. Neurobiol. 21, 15-28.
20. Carlson G.A., Borchelt D.R., Dake A., Turner S., Danielson V., Coffin J.D., Eckman C., Meiners J., Nilsen S.P., Younkin S.G. and Hsiao K.K. (1997). Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum. Mol. Genet. 6, 1951-1959.
21. Carlson C.D., Czilli D.L. and Gitter B.D. (2000). Regulation of amyloid precursor protein processing by A beta in human glioma cells. Neurobiol. Aging 21, 747-756.
22. Casas C., Sergeant N., Itier J.M., Blanchard V., Wirths O., van der K.N., Vingtdeux V., van de S.E., Ret G., Canton T., Drobecq H., Clark A., Bonici B., Delacourte A., Benavides J., Schmitz C., Tremp G., Bayer T.A., Benoit P. and Pradier L. (2004). Massive CA1/2 neuronal loss with intraneuronal and N-interminal truncated A beta(42) accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 165, 1289-1300.
23. Chang L., Bakhos L., Wang Z., Venton D.L. and Klein W.L. (2003). Femtomole immunodetection of synthetic and endogenous amyloidbeta oligomers and its application to Alzheimer's disease drug candidate screening. J. Mol. Neurosci. 20, 305-313.
24. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y.S., Huang X.D., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L. and Bush A.I. (2001). Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676.
25. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P. and Westaway D. (2001). Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 21562-21570.
26. Chui D.H., Shirotani K., Tanahashi H., Akiyama H., Ozawa K., Kunishita T., Takahashi K., Makifuchi T. and Tabira T. (1998). Both n-terminal and c-terminal fragments of presenilin-1 colocalize with neurofibrillary tangles in neurons and dystrophic neurites of senile plaques in alzheimers-disease. J. Neurosci. Res. 53, 99-106.
27. Chung H., Brazil M.I., Soe T.T. and Maxfield F.R. (1999). Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J. Biol. Chem. 274, 32301-32308.
28. Colton C.A., Vitek M.P., Wink D.A., Xu Q., Cantillana V., Previti M.L., Van Nostrand W.E., Weinberg B. and Dawson H. (2006). NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 103, 12867-12872.
29. Culbert A.A., Skaper S.D., Howlett D.R., Evans N.A., Facci L., Soden P.E., Seymour Z.M., Guillot F., Gaestel M. and Richardson J.C. (2006). MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 281, 23658-23667.
30. Davies C.A., Mann D.M., Sumpter P.Q. and Yates P.O. (1987). A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci. 78, 151-164.
31. Dawson G.R., Seabrook G.R., Zheng H., Smith D.W., Graham S., O'Dowd G., Bowery B.J., Boyce S., Trumbauer M.E., Chen H.Y., Van der Ploeg L.H. and Sirinathsinghji D.J. (1999). Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90, 1-13.
32. Dawson R. Jr, Marschall E.G., Chan K.C., Millard W.J., Eppler B. and Patterson T.A. (1998). Neurochemical and neurobehavioral effects of neonatal administration of beta-N-methylamino-L-alanine and 3,3′-iminodipropionitrile. Neurotox. Teratol. 20, 181-192.
33. Delatour B., Blanchard V., Pradier L. and Duyckaerts C. (2004). Alzheimer pathology disorganizes cortico-cortical circuitry: direct evidence from a transgenic animal model. Neurobiol. Dis. 16, 41-47.
34. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M. and Holtzman D.M. (2001). Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98, 8850-8855.
35. DiCarlo G., Wilcock D., Henderson D., Gordon M. and Morgan D. (2001). Intrahippocampal LPS injections reduce A beta load in APP+PS1 transgenic mice. Neurobiol. Aging 22, 1007-1012.
36. Dong H.X., Martin M.V., Chambers S. and Csernansky J.G. (2007). Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice. J. Comp. Neurol. 500, 311-321.
37. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Pereztur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J. and Younkin S. (1996). Increased amyloid-beta-42(43) in brains of mice expressing mutant presenilin-1. Nature 383, 710-713.
38. Dyrks T., Dyrks E., Masters C.L. and Beyreuther K. (1993). Amyloidogenicity of rodent and human beta A4 sequences. FEBS Lett. 324, 231-236.
39. Fonseca M.I., Zhou J., Botto M. and Tenner A.J. (2004). Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosc. 24, 6457-6465.
40. Frautschy S.A., Cole G.M. and Baird A. (1992). Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am. J. Pathol. 140, 1389-1399.
41. Frautschy S.A., Yang F., Irrizarry M., Hyman B., Saido T.C., Hsiao K. and Cole G.M. (1998). Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 152, 307-317.
42. Frenkel D., Maron R., Burt D.S. and Weiner H.L. (2005). Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 115, 2423-2433.
43. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnsonwood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoyazavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B. and Zhao J. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing v717f beta-amyloid precursor protein. Nature 373, 523-527.
44. Glenner G.G. and Wong C.W. (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890.
45. Gomez-Isla T., Wasco W., Pettingell W.P., Gurubhagavatula S., Schmidt S.D., Jondro P.D., Mcnamara M., Rodes L.A., DiBlasi T., Growdon W.B., Seubert P., Schenk D., Growdon J.H., Hyman B.T. and Tanzi R.E. (1997). A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. Ann. Neurol. 41, 809-813.
46. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A. and Klein W.L. (2003). Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100, 10417-10422.
47. Green K.N., Billings L.M., Roozendaal B., McGaugh J.L. and Laferla F.M. (2006). Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J. Neurosci. 26, 9047-9056.
48. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L. and Araoz C. (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA 86, 7611-7615.
49. Hardy J.A. and Higgins G.A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
50. Harigaya Y., Tomidokoro Y., Ikeda M., Sasaki A., Kawarabayashi T., Matsubara E., Kanai M., Saido T.C., Younkin S.G. and Shoji M. (2006). Type-specific evolution of amyloid plaque and angiopathy in APPsw mice. Neurosci. Lett. 395, 37-41.
51. Haroutunian V., Perl D.P., Purohit D.P., Marin D., Khan K., Lantz M., Davis K.L. and Mohs R.C. (1998). Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch. Neurol. 55, 1185-1191.
52. Harrington A.W., Leiner B., Blechschmitt C., Arevalo J.C., Lee R., Morl L., Meyer M., Hempstead B.L., Yoon S.O. and Giehl K.M. (2004). Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc. Natl. Acad. Sci. USA 101, 6226-6230.
53. Heneka M.T., Ramanathan M., Jacobs A.H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., Sastre M., Galldiks N., Zimmer A., Hoehn M., Heiss W.D., Klockgether T. and Staufenbiel M. (2006). Locus Ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26, 1343-1354.
54. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F. and Landreth G.E. (2005). Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453.
55. Hensley K., Floyd R.A., Zheng N.Y., Nael R., Robinson K.A., Nguyen X., Pye Q.N., Stewart C.A., Geddes J., Markesbery W.R., Patel E., Johnson G.V.W. and Bing G.Y. (1999). p38 kinase is activated in the Alzheimer's disease brain. J. Neurochem. 72, 2053-2058.
56. Hilbich C., Kisters-Woike B., Reed J., Masters C.L. and Beyreuther K. (1991). Human and rodent sequence analogs of Alzheimer's amyloid beta A4 share similar properties and can be solubilized in buffers of pH 7.4. Eur. J. Biochem. 201, 61-69.
57. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J.F., Hofmann M., Maddalena A., Papassotiropoulos A. and Nitsch R.M. (2003). Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554.
58. Holcomb L., Gordon M.N., Mcgowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K. and Duff K. (1998). Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97-100.
59. Howlett D.R. (2000). Association of JNK immunoreactivity with βamyloid/tau deposits in transgenic mouse brain. Alz. Rep. 3, 11-14.
60. Howlett D.R. (2001) Aβ oligomerization: a therapeutic target for Alzheimer's disease. Curr. Med. Chem. 1, 25-38.
61. Howlett D.R., Allsop D. and Karran E. (2001). The biology and molecular pathology of β-amyloid protein. In: Neurobiology of Alzheimer's disease. Dawbarn D. and Allen S.J., (eds). Oxford University Press. Oxford. pp 75-102..
62. Howlett D.R., Richardson J.C., Austin A., Parsons A.A., Bate S.T., Davies D.C. and Gonzalez M.I. (2004). Cognitive correlates of A beta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 1017, 130-136.
63. Howlett D.R., Bowler K., Soden P., Riddell D.R., Davis J.B., Richardson J.C., Burbidge S.A., Gonzalez M.I., Irving E.A., Lawman A., Miglio G., Dawson E.L., Howlett E.R. and Hussain I. (2008). Aβ deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease. Histol. Histopathol. 23, 67-76.
64. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A. and Mucke L. (1999). Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96, 3228-3233.
65. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F. and Cole G. (1996). Correlative memory deficits, ∞, elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
66. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., Iadecola C., Clarck H.B. and Clarckson G. (1995). Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15, 1203-1218.
67. Hussain I., Hawkins J., Harrison D., Hille C., Wayne G., Cutler L., Buck T., Walter D., Demont E., Howes C., Naylor A., Jeffrey P., Gonzalez M.I., Dingwall C., Michel A., Redshaw S. and Davis J.B. (2007). Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J. Neurochem. 100, 802-809.
68. Irizarry M.C., Soriano F., Mcnamara M., Page K.J., Schenk D., Games D. and Hyman B.T. (1997). A-beta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein v717f (pdapp) transgenic mouse. J. Neurosci. 17, 7053-7059.
69. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., George-Hyslop P. and Westaway D. (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
70. Kalback W., Watson M.D., Kokjohn T.A., Kuo Y.M., Weiss N., Luehrs D.C., Lopez J., Brune D., Sisodia S.S., Staufenbiel M., Emmerling M. and Roher A.E. (2002). APP transgenic mice Tg2576 accumulate A beta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 41, 922-928.
71. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H. and Younkin S.G. (2001). Age-dependent changes in brain, CSF, and plasma amyloid beta protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372-381.
72. Kelly P.H., Bondolfi L., Hunziker D., Schlecht H.P., Carver K., Maguire E., Abramowski D., Wiederhold K.H., Sturchler-Pierrat C., Jucker M., Bergmann R., Staufenbiel M. and Sommer B. (2003). Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol. Aging 24, 365-378.
73. Kidd M. (1963). Paired helical filaments in electron microscopy in Alzheimer's disease. Nature 197, 192-193.
74. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N. and Laferla F.M. (2005). Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 8843-8853.
75. Kivipelto M., Solomon A. and Winblad B. (2005). Statin therapy in Alzheimer's disease. Lancet Neurol. 4, 521-522.
76. Kokubo H., Kayed R., Glabe C.G. and Yamaguchi H. (2005). Soluble A beta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res. 1031, 222-228.
77. Komitova M., Mattsson B., Johansson B.B. and Eriksson P.S. (2005) Enriched environment increases neural stem/progenitor cell proliferation and neurogenesis in the subventricular zone of stroke-lesioned adult rats. Stroke 36, 1278-82.
78. Kulnane L.S. and Lamb B.T. (2001). Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol. Dis. 8, 982-992.
79. Kuo Y.M., Kokjohn T.A., Beach T.G., Sue L.I., Brune D., Lopez J.C., Kalback W.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M. and Roher A.E. (2001). Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 276, 12991-12998.
80. Kurt M.A., Davies D.C., Kidd M., Duff K. and Howlett D.R. (2003). Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol. Dis. 14, 89-97.
81. Kurt M.A., Davies D.C., Kidd M., Duff K., Rolph S.C., Jennings K.H. and Howlett D.R. (2001). Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp. Neurol. 171, 59-71.
82. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A. and Klein W.L. (1998). Diffusible, nonfibrillar ligands derived from a-beta(1-42) are potent central-nervous-system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448-6453.
83. Lanz T.A., Fici G.J. and Merchant K.M. (2005). Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J. Pharm. Exp. Ther. 312, 399-406.
84. Lanz T.A., Himes C.S., Pallante G., Adams L., Yamazaki S., Amore B. and Merchant K.M. (2003). The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J. Pharm. Exp. Ther. 305, 864-871.
85. Lazarov O., Robinson J., Tang Y.P., Hairston I.S., Korade-Mirnics Z., Lee V.M.Y., Hersh L.B., Sapolsky R.M., Mirnics K. and Sisodia S.S. (2005). Environmental enrichment reduces A beta levels and amyloid deposition in transgenic mice. Cell 120, 701-713.
86. Lee E.B., Leng L.Z., Lee V.M. and Trojanowski J.Q. (2005). Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett. 579, 2564-2568.
87. Lehman E.J., Kulnane L.S., Gao Y., Petriello M.C., Pimpis K.M., Younkin L., Dolios G., Wang R., Younkin S.G. and Lamb B.T. (2003). Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. Hum. Mol. Gen. 12, 2949-2956.
88. Lemere C.A., Spooner E.T., LaFrancois J., Malester B., Mori C., Leverone J.F., Matsuoka Y., Taylor J.W., DeMattos R.B., Holtzman D.M., Clements J.D., Selkoe D.J. and Duff K.E. (2003a). Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice. Neurobiol. Dis. 14, 10-18.
89. Lemere C.A., Spooner E.T., Leverone J.F., Mori C., Iglesias M., Bloom J.K. and Seabrook T.J. (2003b). Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice. Neurochem. Res. 28, 1017-1027.
90. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M. and Ashe K.H. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
91. Leuba G., Saini K., Zimmermann V., Giannakopoulos P. and Bouras C. (2001). Mild amyloid pathology in the primary visual system of nonagenarians and centenarians. Dem. Ger. Cog. Dis. 12, 146-152.
92. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A. and Cole G.M. (2000). Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714.
93. Lim G.P., Chu T., Yang F.S., Beech W., Frautschy S.A. and Cole G.M. (2001). The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 8370-8377.
94. Lim G.P., Calon F., Morihara T., Yang F.S., Teter B., Ubeda O., Salem N., Frautschy S.A. and Cole G.M. (2005). A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25, 3032-3040.
95. Mackenzie I.R.A. and Munoz D.G. (1998). Nonsteroidal antiinflammatory drug-use and alzheimer-type pathology in aging. Neurology 50, 986-990.
96. Masliah E., Sisk A., Mallory M. and Games D. (2001). Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. J. Neuropath. Exp. Neurol. 60, 357-368.
97. Masliah E., Terry R.D., Alford M., DeTeresa R. and Hansen L.A. (1991). Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am. J. Pathol. 138, 235-246.
98. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L. and Beyreuther K. (1985). Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82, 4245-4249.
99. Matsuoka Y., Picciano M., Malester B., LaFrancois J., Zehr C., Daeschner J.M., Olschowka J.A., Fonseca M.I., O'Banion M.K., Tenner A.J., Lemere C.A. and Duff K. (2001). Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 158, 1345-1354.
100. Mattson M.P., Cheng B., Culwell A.R., Esch F.S., Lieberburg I. and Rydel R.E. (1993). Evidence for excitoprotective and intraneuronal calcium- regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10, 243-254.
101. McGeer P.L., McGeer E., Rogers J. and Sibley J. (1990). Anti-inflammatory drugs and Alzheimer disease. Lancet 335, 1037.
102. McGowan E., Sanders S., Iwatsubo T., Takeuchi A., Saido T., Zehr C., Yu X., Uljon S., Wang R., Mann D., Dickson D. and Duff K. (1999). Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis. 6, 231-244.
103. Meyer-Luehmann M., Stalder M., Herzig M.C., Kaeser S.A., Kohler E., Pfeifer M., Boncristiano S., Mathews P.M., Mercken M., Abramowski D., Staunfenbiel M. and Jucker M. (2003). Extracellualar amyloid formation and associated pathology in neural grafts. Nat. Neurosci. 6, 370-377.
104. Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Van den Haute C.V., Checler F., Godaux E., Cordell B. and Van Leuven F. (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483-6492.
105. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K. and McConlogue L. (2000). High-level neuronal expression of Aβ 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050-4058.
106. Munch G., Apelt J., Rosemarie K.E., Stahl P., Luth H.J. and Schliebs R. (2003). Advanced glycation endproducts and pro-inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology. J. Neurochem. 86, 283-289.
107. Nathan C., Calingasan N., Nezezon J., Ding A.H., Lucia M.S., La Perle K., Fuortes M., Lin M., Ehrt S., Kwon N.S., Chen J.Y., Vodovotz Y., Kipiani K. and Beal M.F. (2005). Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J. Exp. Med. 202, 1163-1169.
108. Nicoll J.A.R., Wilkinson D., Holmes C., Steart P., Markham H. and Weller R.O. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448-452.
109. Nilsson L.N., Bales K.R., DiCarlo G., Gordon M.N., Morgan D., Paul S.M. and Potter H. (2001). Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 1444-1451.
110. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y. and Laferla F.M. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular A beta and synaptic dysfunction. Neuron 39, 409-421.
111. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A. and Hock C. (2003). Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46-54.
112. Pasinetti G.M., Zhao Z., Qin W., Ho L., Shrishailam Y., MacGrogan D., Ressmann W., Humala N., Liu X., Romero C., Stetka B., Chen L., Ksiezak-Reding H. and Wang J. (2007). Caloric intake and Alzheimer's disease. Experimental approaches and therapeutic implications. Int. Topics Gerontol. 35, 159-175.
113. Patel N.V., Gordon M.N., Connor K.E., Good R.A., Engelman R.W., Mason J., Morgan D.G., Morgan T.E. and Finch C.E. (2005). Caloric restriction attenuates A beta-deposition in Alzheimer transgenic models. Neurobiol. Aging 26, 995-1000.
114. Permanne B., Adessi C., Fraga S., Frossard M.J., Saborio G.P. and Soto C. (2002). Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease? J. Neural Trans. Suppl., 62, 293-301.
115. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M. and Jucker M. (2002). Cerebral hemorrhage after passive anti-A beta immunotherapy. Science 298, 1379.
116. Phinney A.L., Calhoun M.E., Wolfer D.P., Lipp H.P., Zheng H. and Jucker M. (1999). No hippocampal neuron or synaptic bouton loss in learning-impaired aged beta-amyloid precursor protein-null mice. Neuroscience 90, 1207-1216.
117. Puig B., Gomez-Isla T., Ribe E., Cuadrado M., Torrejon-Escribano B., Dalfo E. and Ferrer I. (2004). Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding beta A plaques in APP Tg2576 mice. Neuropath. Appl. Neurobiol. 30, 491-502.
118. Qiao X.X., Cummins D.J. and Paul S.M. (2001). Neuroinflammation-induced deposition in the APP(V717F) acceleration of amyloid transgenic mouse. Eur. J. Neurosci. 14, 474-482.
119. Quon D., Wang Y., Catalano R., Scardina J.M., Murakami K. and Cordell B. (1991). Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 352, 239-241.
120. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M. and Jucker M. (2006). A beta 42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7, 940-946.
121. Redwine J.M., Kosofsky B., Jacobs R.E., Games D., Reilly J.F., Morrison J.H., Young W.G. and Bloom F.E. (2003). Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: A magnetic resonance microscopy and stereologic analysis. Proc. Natl. Acad. Sci. USA 100, 1381-1386.
122. Refolo L.M., Pappolla M.A., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K. and Duff K. (2000). Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321-331.
123. Reilly J.F., Games D., Rydel R.E., Freedman S., Schenk D., Young W.G., Morrison J.H. and Bloom F.E. (2003). Amyloid deposition in the hippocampus and entorhinal cortex: Quantitative analysis of a transgenic mouse model. Proc. Natl. Acad. Sci. USA 100, 4837-4842.
124. Richardson J.C., Kendal C.E., Anderson R., Priest F., Gower E., Soden P., Gray R., Topps S., Howlett D.R., Lavender D., Clarke N.J., Barnes J.C., Haworth R., Stewart M.G. and Rupniak H.T.R. (2003). Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease. Neuroscience 122, 213-228.
125. Rissman R.A., Poon W.W., Blurton-Jones M., Oddo S., Torp R., Vitek M.P., Laferla F.M., Rohn T.T. and Cotman C.W. (2004). Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121-130.
126. Rockenstein E., Mallory M., Mante M., Sisk A. and Masliaha E. (2001). Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of A beta(1-42). J. Neurosci. Res. 66, 573-582.
127. Rolland Y., Pillard F., Klapouszczak A., Reynish E., Thomas D., Andrieu S., Riviere D. and Vellas B. (2007). Exercise program for nursing home residents with Alzheimer's disease: a 1-year randomized, controlled trial. J. Amer. Ger. Soc. 55, 158-165.
128. Rutten B.P., Van der Kolk N.M., Schafer S., van Zandvoort M.A., Bayer T.A., Steinbusch H.W. and Schmitz C. (2005). Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. Am. J. Pathol. 167, 161-173.
129. Savage M.J., Lin Y.G., Ciallella J.R., Flood D.G. and Scott R.W. (2002). Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J. Neurosci. 22, 3376-3385.
130. Scheff S.W. and Price D.A. (2003). Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol. Aging 24, 1029-1046.
131. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J.P., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z.M., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D. and Seubert P. (1999). Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
132. Schmitz C., Rutten B.P.F., Pielen A., Schafer S., Wirths O., Tremp G., Czech C., Blanchard V., Multhaup G., Rezaie P., Korr H., Steinbusch H.W.M., Pradier L. and Bayer T.A. (2004). Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 164, 1495-1502.
133. Schwab C., Hosokawa M. and McGeer P.L. (2004). Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp. Neurol. 188, 52-64.
134. Seabrook G.R. and Rosahl T.W. (1999). Transgenic animals relevant to Alzheimer's disease. Neuropharm. 38, 1-17.
135. Selkoe D.J., Bell D.S., Podlisny M.B., Price D.L. and Cork L.C. (1987). Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 235, 873-877.
136. Selznick L.A., Holtzman D.M., Han B.H., Gokden M., Srinivasan A.N., Johnson E.M. and Roth K.A. (1999). In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. J. Neuropathol. Exp. Neurol. 58, 1020-1026.
137. Sheng J.G., Bora S.H., Xu G., Borchelt D.R., Price D.L. and Koliatsos V.E. (2003). Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol. Dis. 14, 133-145.
138. Sheng J.G., Mrak R.E., Bales K.R., Cordell B., Paul S.M., Jones R.A., Woodward S., Zhou X.Q., McGinness J.M. and Griffin W.S. (2000). Overexpression of the neuritotrophic cytokine S100beta precedes the appearance of neuritic beta-amyloid plaques in APPV717F mice. J. Neurochem. 74, 295-301.
139. Sheng J.G., Price D.L. and Koliatsos V.E. (2002). Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of A beta amyloidosis. J. Neurosci. 22, 9794-9799.
140. Shie F.S., LeBoeur R.C. and Jin L.W. (2003). Early intraneuronal A beta deposition in the hippocampus of APP transgenic mice. Neuroreport 14, 123-129.
141. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B. and Wisniewski T. (2001). Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159, 439-447.
142. Simard A.R., Soulet D., Gowing G., Julien J.P. and Rivest S. (2006). Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489-502.
143. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M. and Perry G. (1998). Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70, 2212-2215.
144. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., Wasser D., Johnson-Traver S., Lochhead J. and Ziolwolski C. (2005). Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 62, 753-757.
145. Stalder A.K., Pagenstecher A., Yu N.C., Kincaid C., Chiang C.S., Hobbs M.V., Bloom F.E. and Campbell I.L. (1997). Lipopolysaccharide-induced il-12 expression in the central nervous system and cultured astrocytes and microglia. J. Immunol. 159, 1344-1351.
146. Stalder M., Deller T., Staufenbiel M. and Jucker M. (2001). 3D-reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol. Aging 22, 427-434.
147. Sturchler Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M. and Sommer B. (1997). Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 94, 13287-13292.
148. Tahara K., Kim H.D., Jin J.J., Maxwell J.A., Li L. and Fukuchi K. (2006). Role of toll-like receptor signalling in A beta uptake and clearance. Brain 129, 3006-3019.
149. Takahashi R.H., Almeida C.G., Kearney P.F., Yu F.M., Lin M.T., Milner T.A. and Gouras G.K. (2004). Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24, 3592-3599.
150. Takeuchi A., Irizarry M.C., Duff K., Saido T.C., Hsiao A.K., Hasegawa M., Mann D.M., Hyman B.T. and Iwatsubo T. (2000). Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 157, 331-339.
151. Tanzi R.E., Bird E.D., Latt S.A. and Neve R.L. (1987). The amyloid beta protein gene is not duplicated in brains from patients with Alzheimer's disease. Science 238, 666-669.
152. Terai K., Iwai A., Kawabata S., Tasaki Y., Watanabe T., Miyata K. and Yamaguchi T. (2001). Beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease. Neuroscience 104, 299-310.
153. Tsai J., Grutzendler J., Duff K. and Gan W.B. (2004). Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat. Neurosci. 7, 1181-1183.
154. Urbanc B., Cruz L., Le R., Sanders J., Ashe K.H., Duff K., Stanley H.E., Irizarry M.C. and Hyman B.T. (2002). Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 13990-13995.
155. Van Dam D., D'Hooge R., Staufenbiel M., Van Ginneken C., Van Meir F. and De Deyn P.P. (2003). Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci. 17, 388-396.
156. Van Dorpe J., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van den H.C., Mercken M., Moechars D., Laenen I., Kuiperi C., Bruynseels K., Tesseur I., Loos R., Vanderstichele H., Checler F., Sciot R. and Van Leuven F. (2000). Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am. J. Pathol. 157, 1283-1298.
157. van Groen T., Kiliaan A.J. and Kadish I. (2006). Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol. Dis. 23, 653-662.
158. Vardy E.R.L.C., Catto A.J. and Hooper N.M. (2005). Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol. Med. 11, 464-472.
159. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J. and Selkoe D.J. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal longterm potentiation in vivo. Nature 416: 535-539.
160. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A. and Trommer B.L. (2002). Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133-140.
161. Wang J., Ho L., Qin W.P., Rocher A.B., Seror I., Humala N., Maniar K., Dolios G., Wang R., Hof P.R. and Pasinetti G.M. (2005). Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J. 19, 659-661.
162. Ward R.V., Jennings K.H., Jepras R., Neville W., Owen D.E., Hawkins J., Christie G., Davis J.B., George A., Karran E.H. and Howlett D.R. (2000). Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. Biochem. J. 348, 137-144.
163. Weiner H.L. and Frenkel D. (2006). Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 6, 404-416.
164. Wengenack T.M., Whelan S., Curran G.L., Duff K.E. and Poduslo J.F. (2000). Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience 101, 939-944.
165. White J.A., Manelli A.M., Holmberg K.H., Van Eldik L.J. and Ladu M.J. (2005). Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol. Dis. 18, 459-465.
166. Wirths O., Multhaup G., Czech C., Feldmann N., Blanchard V., Tremp G., Beyreuther K., Pradier L. and Bayer T.A. (2002). Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol. 12, 275-286.
167. Wong T.P., Debeir T., Duff K. and Cuello A.C. (1999). Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci. 19, 2706-2716.
168. Wood W.G., Igbavboa U., Eckert G.P., Johnson-Anuna L.N. and Muller W.E. (2005). Is hypercholesterolemia a risk factor for Alzheimer's disease? Mol. Neurobiol. 31, 185-192.
169. Wu C.C., Chawla F., Games D., Rydel R.E., Freedman S., Schenk D., Young W.G., Morrison J.H. and Bloom F.E. (2004). Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: Digital morphometric analyses. Proc. Natl. Acad. Sci. USA 101, 7141-7146.
170. Wu Z.L., Ciallella J.R., Flood D.G., O'Kane T.M., Bozyczko-Coyne D. and Savage M.J. (2006). Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol. Aging 27, 377-386.
171. Zhang C., McNeil E., Dressler L. and Siman R. (2007). Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer's disease. Exp. Neurol. 204, 77-87.